Список литературы

Поставить закладку

van der Post R.S., Vogelaar I.P., Carneiro F. et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015;52(6):361–74.
Petrovchich I., Ford JM. Genetic predisposition to gastric cancer. SeminOncol 2016;43(5):554–9.
Поддубная И.В., Каприн А.Д., Лядов В.К. Классификация опухолей TNM. 8-я ред. Руководство и атлас. Т. I: Опухоли торакоабдоминальной локализации. М.; Практическая медицина, 2018. – 424 с.
SmythE.C., VerheijM., AllumW. E tal. Gastric Cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2016; 27(suppl. 5):v38–v49, https://www.esmo.org/Guidelines/Gastro-intestinal-Cancers/Pan-Asian-adapted-ESMO-Clinical-Practice-Guidelines-for-the-management-of-patients-with-metastatic-gastric-cancer (accessed on October 10, 2019).
Bray F., Ferlay J., Soerjomataram I. et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: ACancerJournalforClinicians 2018;0:1–31.
Fukayama M., Rugge M., Washington M.K. Tumours of the stomach. In: WHO Classification of Tumours Editorial Board. Digestive Tumours. Lyon (France): IARC 2019;59–109.
Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer (2011) 14:101–112.
Wanebo H.J., Kennedy B.J., Chmiel J. et al. Cancer of the stomach. A patient care study by the American College of Surgeons. AnnSurg 1993;218(5):583.
Щепотин И.Б., Эванс С.Р. Рак желудка: практическое руководство по профилактике, диагностике и лечению. Киев; «Книга Плюс», 2000. – 227 с.
Березов Ю.Е. Хирургия рака желудка. М.; Медицина, 1976 г. – 352 с.
Русанов А.А. Рак желудка. М.; Медицина, 1979. – 180 с.
MatsumotoY., YanaiH., TokiyamaH. etal. Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric cancer.J Gastroenterol 2000;35(5):326–31.
Cardoso R., Coburn N., Seevaratnam R. et al. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. Gastric Cancer
2012;15(Suppl 1):S19–26. 152Watt I. et al.
Spolverato G., Ejaz A., Kim Y. et al. Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative. J Am Coll Surg 2015;220(1):48–56.
MurataY., SuzukiS., OgumaH. etal. Recent progress in staging gastric cancer by endoscopic ultrasonography. Proceeding of 3rd International Gastric Cancer Congress, Seoul, Korea, 1999.
Watt I. et al. Laparoscopy, ultrasound and computed tomography in cancer of the oesophagus and gastric cardia: a prospective comparison for detecting intra‐abdominal metastases //British journal of surgery. – 1989. – Т. 76. – №. 10. – С. 1036-1039.
Chen C.Y., Hsu J.S., Wu D.C. et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT-correlation with surgical and histopathologic results. Radiology 2007;242:472–82.
Fukuya T., Honda H., Kaneko K. et al. Efficacy of helical CT in T staging of gastric cancer. J Comput Assist Tomography 1997;(21):73–81.
Takao M., Fukuda T., Iwanaga S. et al. Gastric cancer: evaluation of triphasic spiral CT and radiologic–pathologic correlation. J Comput Assist Tomography 1998;(22):288–94.
Kong J. H. et al. Lung metastases in metastatic gastric cancer: pattern of lung metastases and clinical outcome //Gastric Cancer. – 2012. – Т. 15. – №. 3. – С. 292-298
Liao S. R. et al. Transabdominal ultrasonography in preoperative staging of gastric cancer //World Journal of Gastroenterology: WJG. – 2004. – Т. 10. – №. 23. – С. 3399.
Karanicolas P.J., Elkin E.B., Jacks L.M. et al. Staging Laparoscopy in the Management of Gastric Cancer: A Population-Based Analysis. J Am Coll Surg 2011;213:644–51.
Leake P.A., Cardoso R., Seevaratnam R. et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer 2012;15(Suppl. 1):S27–37.
Leake P.A., Cardoso R., Seevaratnam R. et al. A systematic review of the accuracy and indications for diagnostic laparoscopy before curative-intent resection of gastric cancer. Gastric Cancer 2012;15(Suppl. 1):S38–47.
Mezhir J.J., Shah M.A., Jacks L.M. et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. AnnSurgOncol 2010;17(12):3173–80. doi: 10.1245/s10434-010-1183-0.
Sarela A.I., Lefkowitz R., Brennan M.F. et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg 2006;191(1):134–8.
van Vliet EP, van der Lugt A, Kuipers EJ et al. Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study. J Surg Oncol. 2007 Sep 1;96(3):200-6.
Lim J.S., Yun M.J., Kim M.J. et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics 2006;26(1):143–56.
Dassen A.E., Lips D.J., Hoekstra C.J. et al. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol. 2009;35(5):449–55. doi: 10.1016/j.ejso.
2008.11.010.
Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer (2003) 98(7):1521–3010.
Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680–6.
Novelli MR. Dataset for the histopathological reporting of gastric carcinoma (2nd edition). The Royal College of Pathologists. 2007:1-15.
Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of malignant tumours. Eighth edition. – 2019:63
Bartley A.N., Washington M.K., Colasacco C. et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society of Clinical Pathology, and American Society of Clinical Oncology. J Clin Oncol 2017;35(4):446–64.
Bartley A.N., Fitzgibbons P.L., Broaddus R.R., Shi C. Template for Reporting Results of DNA Mismatch Repair Testing in Patients Being Considered for Checkpoint Inhibitor Immunotherapy. College of American Pathologists 2018;1–2.
Le D.T., Uram J.N., Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency.N Engl J Med 2015;372:2509–20.
Pimentel-Nunes P., Dinis-Ribeiro M., Ponchon T. et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 2015;47:829–54.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;0:1–19. DOI 10.1007/s10120-016-0622-4.
Adachi Y., Kamakura T., Mori M. et al. Prognostic significance of the number of positive lymph nodes in gastric carcinoma.Br J Surg 1994;81:414–6.
Ito H., Oohata Y., Nakamura K. et al. Complete ten-year postgastrectomy follow-up of early gastric cancer. Am J Surg 1989;158:14–16.
Isozaki H., Okajima K., Ichinowa T. et al. Distant lymph node metastasis of early gastric cancer. Jpn J Surg 1997;27:600–5.
Takagi M., Katai H., Mizusawa J. et al. A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912): Analysis of the safety and short-term clinical outcomes. J Clin Oncol 2015;33, (15):4017–17. DOI: 10.1200/jco.2015.33.15_suppl.4017.
Kim W., Kim H.H., Han S.U. et al. Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). AnnSurg 2016;263(1):28–35.
Давыдов М.И., Тер-Ованесов М.Д., Полоцкий Б.Е. и др. Рак желудка. В кн.: Энциклопедия клинической онкологии: М.И. Давыдов (ed.). М.; РЛС, 2004. – С. 223–30.
Давыдов М.И., Туркин И.Н., Давыдов М.М.. Энциклопедия хирургии рака желудка: Давыдов М.И. (ed.). М.; ЭКСМО, 2011. – С. 536.
СтилидиИ.С., НередС.Н. Современныепредставленияобосновныхпринципаххирургическоголеченияместно-распространенного рака желудка. Практ. онкология, 2009;10(1):20-7.
Hu Y., Huang C., Sun Y. etal. Laparoscopic D2 subtotal gastrectomy versus conventional open surgery for advanced gastric cancer: The safety analysis from a multicenter prospective randomized controlled trial in China (CLASS-01 trial). J Clin Oncol 2015;33:3_suppl. 122–22. DOI: 10.1200/jco.2015.33.3_suppl.122.
Quan Y., Huang A., Ye M. et al. Comparison of laparoscopic versus open gastrectomy for advanced gastric cancer: an updated meta-analysis. Gastric Cancer 2016;19:939–50.
Lee J.H., Nam B.H., Ryu K.W. et al. Comparison of outcomes after laparoscopy-assisted and open total gastrectomy for early gastric cancer. Br J Surg 2015;102:1500–5.
Lee H.J., Hyung W.J., Yang H.K. et al. Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT). Ann Surg 2019;9. doi: 10.1097/SLA.0000000000003217.
LeeS.W., EtohT., OhyamaT. etal. Short-term outcomes from a multi-institutional, phase III study of laparoscopic versus open distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). J Clin Oncol 35;15_suppl:4029–29. DOI: 10.1200/JCO.2017.35.15_suppl.4029.
Songun I.,Putter H., Kranenbarg E.M. et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11(5):439–49. doi: 10.1016/S1470-2045(10)70070-X.
Sasako M., Sano T., Yamamoto S. et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359(5):453.
Sano T., Sasako M., Mizusawa J. et al Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg 2017;265(2):277–83. doi: 10.1097/SLA.0000000000001814.
Yu W., Choi G.S., Chung H.Y. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer.Br J Surg 2006;93(5):559–63.
Cunningham D., Allum W.H., Stenning S.P. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med 2006;355:11–20.
Ychou M., Pignon J.P., Lasser P. et al. Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (C) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNCLCC 94012 FFCD 9703 trial. Proc Am Soc Clin Oncol. 2006;24(18S):Abstr. 4026.
Al-Batran S.E., Homann N., Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastricor gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57. doi: 10.1016/S0140-6736(18)32557-1.
Wang X, Zhao L, Liu H, et al. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer.// Br J Cancer. - 2016 Jun 14;114(12):1326-33. doi: 10.1038/bjc.2016.126.
Yu Y, Fang Y, Shen Z, et al. Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study. //Oncologist. 2019 Oct ;24(10):1311-e989. doi: 10.1634/theoncologist.2019-041.
Sakuramoto S., Sasako M., Yamaguchi T. et al. Adjuvant chemotherapy for gastric cancer with S‑1, an oral fluoropyrimidine.N Engl J Med 2007;357:1810–20.
Noh S.H., Park S.R., Yang H.K. et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389–96.
Dikken J.L., Jansen E.P., Cats A. et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010;28:2430–6.
Stiekema J., Trip A.K., Jansen E.P. et al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol 2014;21:1107–14.
Smyth E.C., Wotherspoon A., Peckitt C. et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol 2017;3(9):1197–203. doi: 10.1001/jamaoncol.2016.6762.
Choi Y.Y., Kim H., Shin S.J. et al. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg 2019;270(2):309–16. doi: 10.1097/SLA.0000000000002803.
Macdonald J.S., Smalley S.R., Benedetti J. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30.
Smalley S.R., Benedetti J.K., Haller D.G. et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327–33.
Cats A., Jansen E.P.M., van Grieken N.C.T. et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 2018; pii: S1470‑2045(18)30132–3. doi: 10.1016/S1470-2045(18)30132-3.
Wagner A.D., Grothe W., Haerting J. et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;
24(18):2903–9.
Dank M., Zaluski J., Barone C. et al. Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients, Proc Am Soc Clin Oncol 2005; 23(16s):308s(Abstr. 4003).
Guimbaud R., Louvet C., Ries P. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol 2014;32(31):3520–6. doi: 10.1200/JCO.2013.54.1011.
Osumi H, Takahari D, Chin K, et a.l Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. Onco Targets Ther. 2018 Nov 23;11:8301-8307. doi: 10.2147/OTT.S184665.
Ajani J.A., Moiseyenko V.M., Tjulandin S. et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007.1;25(22):3205–9.
Kang Y.-K., Kang W.-K., Shin D.-B.,et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Annals of Oncology 2009. 20: 666–673. doi:10.1093/annonc/mdn717
Van Cutsem E., Boni C., Tabernero J. et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol 2015;26(1):149–56.
Shah M.A., Janjigian Y.Y., Stoller R. et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. J Clin Oncol 2015;33(33):3874–9.
LeeJ., KangW.K., KwonJ.M. etal. Phase II trial of irinotecan plus oxaliplatin and 5‑fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.Ann Oncol 2007;18(1):88–92.
Comella P., Lorusso V., Maiorino L. et al. Oxaliplatin, irinotecan, and fluorouracil/ folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. CancerChemotherPharmacol 2009;64(5):893–9.
Obarevich E., Besova N., Trusilova E., Gorbunova V. Irinotecan, oxaliplatin, 5‑fluorouracil/leucovorin (mFOLFIRINOX) as first-line therapy in advanced Her2-negative gastricorgastroesophageal adenocarcinoma (G/GEA). ESMO-18/ Ann Clin Oncol 2018;29(Supp.8), p-viii227, abstr. 675P.
Park H., Wang-Gillam A., Suresh R. et al. Phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma. J Clin Oncol 2018;36:4_suppl:89–9.
82Трусилова Е.В. Рак желудка. Руководство по химиотерапии опухолевых заболеваний под ред Н.И.Переводчиковой, В.А.Горбуновой. Москва, 2015- стр. 191-208
Ochenduszko S. et al. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial //Medical Oncology. – 2015. – Т. 32. – №. 10. – С. 242.
Okines A.F., Asghar U., Cunningham D. et al. Rechallenge with platinum plus fluoropyrimidine +/– epirubicin in patients with oesophagogastric cancer. Oncology 2010;79:150–8.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
Satoh T. et al. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer //Cancer chemotherapy and pharmacology. – 2012. – Т. 69. – №. 4. – С. 949-955.
Rivera F., Romero C., Jimenez‑Fonseca P.et al.Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemotherapy and Pharmacology, 2019; 83:1175–1181. https://doi.org/10.1007/s00280-019-03820-7
Soularue É., Cohen R., Tournigand C., et al. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study. Bull Cancer 2015; 102: pp 324–331
Zaanan A, PalleJ,Soularue E et al. Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-EsophagealAdenocarcinoma: A Retrospective Multicenter AGEO Study. Targ Oncol 2018, V13, Issue 1, pp 107-112. https://doi.org/10.1007/s11523-017-0531-4
Thuss-Patience P.C., Kretzschmar A., Bichev D. et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47:2306–14. DOI:10.1016/j.ejca.2011.06.002.
Ford H., Marshall A., Wadsley J. et al. Cougar-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. Lancet Oncol 2014;15:78–86. DOI: 10.1016/S1470-2045(13)70549-7.
Kang J.H., Lee S.I., Lim D.H. et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513–8.
Roy A. C., Park S. R., Cunningham D.*, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Annals of Oncology 2013; 24: 1567–1573, doi:10.1093/annonc/mdt002
Hironaka S., Ueda S., Yasui H. et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013;31(35):4438–44.
Di Lauro L., Fattoruso S.I., Giacinti L. et al. Second-line chemotherapy with FOLFIRI in patients with metastatic gastric cancer (MGC) not previously treated with fluoropyrimidines [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstr. 454.
Makiyama A, Sagara K, Kawada J, Kashiwada T, Hosokawa A, Horie Y, Satake H, Yamamoto Y, Tanioka H, Shinozaki K, et al. A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT) J Clin Oncol. 2018;36(15_suppl):4011. doi: 10.1200/JCO.2018.36.15_suppl.4011
Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–653. doi: 10.1016/S1470-2045(17)30111-0.
Ter Veer E. et al. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis //Acta Oncologica. – 2018. – Т. 57. – №. 12. – С. 1599-1604.
Wilke H., Muro K., Van Cutsem E. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014 Oct;15(11):1224–35.
Fuchs C.S., Tomasek J., Yong C.J. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet.2014;383(9911):31–9.
Sakai D., Boku N., Kodera Y., et al. An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).. J Clin Oncol 36, 2018 (suppl; abstr TPS4138)
Бесова Н.С., Титова Т.А., Строяковский Д.Л. и др. Результаты применения рамуцирумаба с иринотеканом и аналогами пиримидина во второй линии лечения больных диссеминированным раком желудка. Мед.совет 2019;10:100–9.
KlempnerS.J., MaronS.B., ChaseK. etal. Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. The Oncologist 2019;24:475–82.
Satake H. et al. Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane //Cancer chemotherapy and pharmacology. – 2018. – Т. 82. – №. 5. – С. 839-845.
Roviello G., Petrioli R., Rosellini P., et al. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. Investigational New Drugs.Published online: 28 January 2019.https://doi.org/10.1007/s10637-019-00725-3
Sym SJ, Ryu MH, Lee JL, et al. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol. 2008 Apr;31(2):151-6. doi: 10.1097/COC.0b013e31815878a2.
Burge M E, Smith D, Topham C, et al. A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br J Cancer. 2006 May 8; 94(9): 1281–1286.Published online 2006 May 2. doi: 10.1038/sj.bjc.6603084
Leary A., Assersohn L., Cunningham D., et al. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.Cancer Chemother Pharmacol.2009; 64:455–462.DOI 10.1007/s00280-008-0893-5108.
Köhne CH, De Greve J, Hartmann JT, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol. 2008 May;19(5):920-6.
Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 25::4779,2007-4786
Fuchs C.S., Doi T., Jang R.W. et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.
Kang Y.K., Boku N., Satoh T. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:2461–71.
Janjigian Y. Y., Bendell J., Calvo E.,et al. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. JClinOncol.2018 Oct 1; 36(28): 2836–2844.
Инструкция по применению лекарственного препарата Опдиво (Opdivo).Утверждена Минздравом России: ЛП -004026 от 19.09.2019. http://grls.rosminzdrav.ru/InstrImg/0001448198/%D0%9B%D0%9F-004026[2019]_0.pdf
Kim Y.I., Choi I.J. Endoscopic management of tumor bleeding from inoperable gastric cancer.ClinEndosc 2015;48(2):121–7. doi: 10.5946/ce.2015.48.2.121.
ImbesiJ.J., KurtzR.C. A multidisciplinary approach to gastrointestinal bleeding in cancer patients. J Support Oncol 2005;3(2):101–10.
Kondoh C., Shitara K., Nomura M. et al. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. BMC Palliat Care 2015;14:37. doi: 10.1186/s12904-015-0034-y.
Kim T.O., Kang D.H., Kim G.H. et al. Self-expandable metallic stents for palliation of patients with malignant gastric outlet obstruction caused by stomach cancer. World J Gastroenterol 2007;13(6):916–20.
Endo S., Takiguchi S., Miyazaki Y. et al. Efficacy of endoscopic gastroduodenal stenting for gastric outlet obstruction due to unresectable advanced gastric cancer: a prospective multicenter study. J Surg Oncol 2014;109(3):208–12. doi: 10.1002/jso.23486.
Jeurnink S.M., Steyerberg E.W., van Hooft J.E. et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc 2010;71(3):490–9.doi: 10.1016/j.gie.2009.09.042.
Ly J., O’Grady G., Mittal A. et al. A systematic review of methods to palliate malignant gastric outlet obstruction. Surg Endosc 2010;24(2):290–7. doi: 10.1007/s00464-009-0577-1.
Issaka R.B., Shapiro D.M., Parikh N.D. et al. Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. Surg Endosc 2014(5):1668–73. doi: 10.1007/s00464-013-3368-7
Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013;92:715–27.
Swarm R.A., Abernethy A.P., Anghelescu D.L. et al. Adult cancer pain. J Natl Compr Canc Netw 2013;11(8):992–1022.
Luther A., Gabriel J., Watson R.P., Francis N.K. The Impact of Total Body Prehabilitation on Post-Operative Outcomes After Major Abdominal Surgery: A Systematic Review. World J Surg. 2018;42(9):2781–91.
Сытов А.В., Лейдерман И.Н., Ломидзе С.В., Нехаев И.В., Хотеев А.Ж. Практические рекомендации по нутритивной поддержке онкологических больных. Злокачественные опухоли : Практические рекомендации RUSSCO #3s2, 2019 (том 9). С. 639–647.
Jie B., Jiang Z.M., Nolan M.T. et al. Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk. Nutrition. 2012;28:1022–7.
Затевахин И.И., Лядов К.В., Пасечник И.Н. (eds.). Программа ускоренного выздоровления хирургических больных Fast track. М.; ГЭОТАР-Медиа, 2017. – 208 с.
Gemmill E.H., Humes D.J., Catton J.A. Systematic review of enhanced recovery after gastro-oesophageal cancer surgery. Ann R Coll Surg Engl 2015;97:173–9.
Feng F., Ji G., Li J.P. et al. Fast-track surgery could improve postoperative recovery in radical total gastrectomy patients. World J Gastroenterol 2013;19(23):3642–8.
Almeida E.P.M., Almeida J.P., Landoni G. et al. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial. Brit J Anaesth 2017;119(5):900–7.
Jo DH, Jeong O, Sun JW, Jeong MR, Ryu SY, Park YK. Feasibility study of early oral intake after gastrectomy for gastric carcinoma. J Gastric Cancer. 2011 Jun;11(2):101-8.
Mortensen K, Nilsson M, Slim K, et al; Enhanced Recovery After Surgery (ERAS®) Group. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Br J Surg. 2014 Sep;101(10):1209-29.
Álvarez-Sarrado E. et al. Feeding Jejunostomy after esophagectomy cannot be routinely recommended. Analysis of nutritional benefits and catheter-related complications. Am J Surg 217;1:114–20.
Sun H.B., Li Y., Liu X.B. et al. Early Oral Feeding Following McKeown Minimally Invasive Esophagectomy: An Open-label, Randomized, Controlled, Non-inferiority Trial. Ann Surg 2018;267(3):435–42.
Steenhagen E., van Vulpen J.K., van Hillegersberg R. et al. Nutrition in peri-operative esophageal cancer management. Expert Review of Gastroenterology Hepatology 2017;11(7):663–72.
Shin K.Y., Guo Y., Konzen B. et al. In patient cancer rehabilitation: the experience of a national comprehensive cancer center. Am J Phys Med Rehabil 2011; 90(5):63–8.
Bourke L., Homer K.E., Thaha M.A. et al. Interventions to improve exercise behavior in sedentary people living with and beyond cancer: a systematic review. Br J Cancer 2014;110:831–41.
Arends J., Bachmann P., Baracos V. et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017;36(1):11–48.
Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Oct;14(10):1286-1312.
Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017;3:961–8.
Kleckner I.R., Kamen C., Gewandter J.S. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018;26:1019–28.
Dennett A.M., Peiris C.L., Shields N. et al. Moderate-intensity exercise reduces fatigue and improves mobility in cancer survivors: a systematic review and meta-regression. J Physio-ther 2016;62(2):68–82.
Streckmann F., Zopf E.M., Lehmann H.C. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014;44:1289–304.
Hou S., Huh B., Kim H.K. et al. Treatment of Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Recommendations. Pain Physician 2018;21:571–92.
Kılınç M1, Livanelioğlu A, Yıldırım SA, Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med. 2014 May;46(5):454-60. doi: 10.2340/16501977-1271.
Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014;9(9):e107418.
He M., Zhang B., Shen N. et al. A systematic review and meta-analysis of the effect of low-level laser therapy (LLLT) on chemotherapy-induced oral mucositis in pediatric and young patients. Eur J Pediatr 2018;177(1):7–17.
Ross M., Fischer-Cartlidge E. Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs 2017;21(2):226–33.
Заридзе Д.Г. Профилактика рака. Руководство для врачей. — М.:ИМА-ПРЕСС, 2009. — c. 29-35.
Van der Post R.S., Vogelaar I.P., Carneiro F., Guilford P., Huntsman D. et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers // J Med Genet. 2015. Vol. 52. P. 361-374.
Syngal S., Brand, RE., Church JM., et al. ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. Am J Gastroenterol. 2015 February ; 110(2): 223–263. doi:10.1038/ajg.2014.435.
Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005;2(1):3. Published 2005 Feb 8. doi:10.1186/1477-7800-2-3
Noriyuki Inaki, Tsuyoshi Etoh, Tetsuji Ohyama, Kazuhisa Uchiyama, Natsuya Katada, Keisuke Koeda, Kazuhiro Yoshida, Akinori Takagane, Kazuyuki Kojima, Shinichi Sakuramoto, Norio Shiraishi, Seigo Kitano // A Multi-institutional, Prospective, Phase II Feasibility Study of Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (JLSSG0901) // World J Surg. 2015 Nov;39(11):2734-41. doi: 10.1007/s00268-015-3160-z. PMID: 26170158
Jiang Yu, Changming Huang, Yihong Sun, Xiangqian Su, Hui Cao, Jiankun Hu, Kuan Wang, Jian Suo, Kaixiong Tao, Xianli He, Hongbo Wei, Mingang Ying, Weiguo Hu, Xiaohui Du, Yanfeng Hu, Hao Liu, Chaohui Zheng, Ping Li, Jianwei Xie, Fenglin Liu, Ziyu Li, Gang Zhao, Kun Yang, Chunxiao Liu, Haojie Li, Pingyan Chen, Jiafu Ji, Guoxin Li, Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group// Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial// JAMA. 2019 May 28;321(20):1983-1992. doi: 10.1001/jama.2019.5359. PMID: 31135850. PMCID: PMC6547120
Hoon Hur, Hyun Yong Lee, Hyuk-Joon Lee, Min Chan Kim, Woo Jin Hyung, Young Kyu Park, Wook Kim, Sang-Uk Han // Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer: the protocol of the KLASS-02 multicenter randomized controlled clinical trial// BMC Cancer. 2015 May 5;15:355. doi: 10.1186/s12885-015-1365-z. PMID: 25939684. PMCID: PMC4432816
Leonie Haverkamp, Hylke J F Brenkman, Maarten F J Seesing, Suzanne S Gisbertz, Mark I van Berge Henegouwen, Misha D P Luyer, Grard A P Nieuwenhuijzen, Bas P L Wijnhoven, Jan J B van Lanschot, Wobbe O de Steur, Henk H Hartgrink, Jan H M B Stoot, Karel W E Hulsewé, Ernst J Spillenaar Bilgen, Jeroen E Rütter, Ewout A Kouwenhoven, Marc J van Det, Donald L van der Peet, Freek Daams, Werner A Draaisma, Ivo A M J Broeders, Henk F van Stel, Miangela M Lacle, Jelle P Ruurda, Richard van Hillegersberg, LOGICA study group// Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial)// BMC Cancer. 2015 Jul 29;15:556. doi: 10.1186/s12885-015-1551-z. PMID: 2621967. PMCID: PMC4518687
Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, Ito S, Kurita A, Mizusawa J, Nakamura K; Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg. 2015 Mar;102(4):341-8. doi: 10.1002/bjs.9764. Epub 2015 Jan 21.PMID: 25605628
Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH. Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. Gynecol Oncol. 2004 Aug;94(2):477-82. doi: 10.1016/j.ygyno.2004.05.007. PMID: 15297191.
Janjigian Y.Y., Shitara K., Moehler M., Garrido M., Salman P., Shen L., et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastrooesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.Published Online June 5, 2021. https://doi.org/10.1016/S0140-6736(21)00797-2
Chen, Y., Kingham, K., Ford, J.M. et al. A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer. Ann Surg Oncol 18, 2594–2598(2011). https://doi.org/10.1245/s10434-011-1648-9
Strong VE, Gholami S, Shah MA et al. Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients. Ann Surg. 2017 Dec;266(6):1006-1012. doi: 10.1097/SLA.0000000000002030.